JP2004538239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004538239A5 JP2004538239A5 JP2001563112A JP2001563112A JP2004538239A5 JP 2004538239 A5 JP2004538239 A5 JP 2004538239A5 JP 2001563112 A JP2001563112 A JP 2001563112A JP 2001563112 A JP2001563112 A JP 2001563112A JP 2004538239 A5 JP2004538239 A5 JP 2004538239A5
- Authority
- JP
- Japan
- Prior art keywords
- ddb
- animals
- ortipraz
- dmn
- alt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 2
- 229950008687 oltipraz Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20000010540 | 2000-03-02 | ||
| PCT/KR2001/000320 WO2001064215A1 (en) | 2000-03-02 | 2001-03-02 | Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004538239A JP2004538239A (ja) | 2004-12-24 |
| JP2004538239A5 true JP2004538239A5 (enExample) | 2005-03-17 |
| JP4226246B2 JP4226246B2 (ja) | 2009-02-18 |
Family
ID=36776473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001563112A Expired - Fee Related JP4226246B2 (ja) | 2000-03-02 | 2001-03-02 | 肝線維症および肝硬変の処置および予防のための薬剤組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1263435B1 (enExample) |
| JP (1) | JP4226246B2 (enExample) |
| CN (1) | CN1218698C (enExample) |
| AT (1) | ATE332693T1 (enExample) |
| AU (1) | AU2001237768A1 (enExample) |
| BR (1) | BR0108732A (enExample) |
| DE (1) | DE60121426T2 (enExample) |
| ES (1) | ES2267722T3 (enExample) |
| RU (1) | RU2250768C2 (enExample) |
| WO (1) | WO2001064215A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030067935A (ko) * | 2002-02-09 | 2003-08-19 | 김상건 | 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물 |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| KR100604261B1 (ko) * | 2004-10-11 | 2006-07-28 | 재단법인서울대학교산학협력재단 | 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물 |
| EP1893211B1 (en) * | 2005-06-17 | 2011-09-14 | Novartis AG | Use of sanglifehrin in hcv |
| CA2651623A1 (en) | 2006-05-11 | 2007-11-22 | Patrick T. Prendergast | Compositions and methods for modulating the immune system |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| AU5474198A (en) * | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
-
2001
- 2001-03-02 JP JP2001563112A patent/JP4226246B2/ja not_active Expired - Fee Related
- 2001-03-02 EP EP01910188A patent/EP1263435B1/en not_active Expired - Lifetime
- 2001-03-02 BR BR0108732-0A patent/BR0108732A/pt not_active Application Discontinuation
- 2001-03-02 AU AU2001237768A patent/AU2001237768A1/en not_active Abandoned
- 2001-03-02 DE DE60121426T patent/DE60121426T2/de not_active Expired - Lifetime
- 2001-03-02 AT AT01910188T patent/ATE332693T1/de not_active IP Right Cessation
- 2001-03-02 ES ES01910188T patent/ES2267722T3/es not_active Expired - Lifetime
- 2001-03-02 RU RU2002126216/15A patent/RU2250768C2/ru not_active IP Right Cessation
- 2001-03-02 CN CNB018059627A patent/CN1218698C/zh not_active Expired - Fee Related
- 2001-03-02 WO PCT/KR2001/000320 patent/WO2001064215A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL140306A0 (en) | Microparticle formulation for inhalation | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| JP2002515453A5 (enExample) | ||
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| JP2002522485A5 (enExample) | ||
| WO2004028480A3 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| JP2002524415A5 (enExample) | ||
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| JP2002528502A5 (enExample) | ||
| JP2004537500A5 (enExample) | ||
| JP2005517040A5 (enExample) | ||
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JP2001520994A5 (enExample) | ||
| WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
| Zein | Interferons in the management of viral hepatitis | |
| JP2004538239A5 (enExample) | ||
| WO2005065429A3 (en) | Composition and method for treatment of hepatic encephalopathy | |
| WO2005004854A3 (fr) | Utilisation de la betaine pour le traitement des arterites | |
| JP2003503453A5 (ja) | ガバペンチンおよびプレガバリンを含む相乗作用組成物 | |
| NO984974L (no) | Middel som forbedrer pulmonar sirkulasjon | |
| WO2003026570A3 (en) | Reduced toxicity cisplatin formulations and methods for using the same | |
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| EP1550443A4 (en) | COMPOSITION AGAINST STRESS-BASED DISEASES | |
| JP2002241310A (ja) | 局所適用組成物 |